Nizatidine

Nizatidine
Clinical data
Trade names	Axid, Tazac
AHFS/Drugs.com	Monograph
MedlinePlus	a694030
License data	US DailyMed: Nizatidine;
Pregnancy; category	AU: B3; ;
Routes of; administration	By mouth
ATC code	A02BA04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / OTC; UK: POM (Prescription only); US: OTC / Rx-only;
Pharmacokinetic data
Bioavailability	>70%
Protein binding	35%
Metabolism	Liver
Elimination half-life	1–2 hours
Excretion	Kidney
Identifiers
	IUPAC name (E)-1-N'-[2-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine;
CAS Number	76963-41-2 ;
PubChem CID	3033637;
IUPHAR/BPS	7248;
DrugBank	DB00585 ;
ChemSpider	2298266 ;
UNII	P41PML4GHR;
KEGG	D00440 ;
ChEBI	CHEBI:7601 ;
ChEMBL	ChEMBL653 ;
CompTox Dashboard (EPA)	DTXSID5023376 ;
ECHA InfoCard	100.155.683
Chemical and physical data
Formula	C12H21N5O2S2
Molar mass	331.45 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [O-][N+](=O)\C=C(/NC)NCCSCc1nc(sc1)CN(C)C;
	InChI InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+ ; Key:SGXXNSQHWDMGGP-IZZDOVSWSA-N ;
	(what is this?) (verify)

Nizatidine is a histamine H₂ receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.^[2]

It was patented in 1980 and approved for medical use in 1988.^[3]^[4] It was developed by Eli Lilly.

^ "Approved in 2020: Drugs for human use". Health Canada. 26 July 2021. Retrieved 27 March 2024.
^ Romero M, Franzosi MG (1989). "[Nizatidine]". Medicina (in Italian). 9 (1): 93–96. PMID 2567957.
^ "Nizatidine: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 20 March 2020.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 44. ISBN 9783527607495.